• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    BD Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results

    11/7/24 6:30:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care
    Get the next $BDX alert in real time by email

    Strong Growth and Margin Execution Drives Performance in Quarter

    • Q4 revenue of $5.4 billion increased 6.9% as reported, 7.4% currency-neutral and 6.2% organic
    • Q4 GAAP and adjusted diluted EPS from continuing operations of $1.45 and $3.81 grew 173.6% and 11.4%, respectively
    • FY24 revenue of $20.2 billion increased 4.2% as reported and currency neutral, 4.6% adjusted currency-neutral, and 5.0% organic
    • FY24 GAAP and adjusted diluted EPS from continuing operations of $5.93 and $13.14 grew 16.3% and 7.6%, respectively
    • FY24 cash from continuing operations grew 28.5% to $3.8 billion and Free Cash Flow grew 47.4% to $3.1 billion, increasing $0.9 billion and $1.0 billion since the prior year, respectively
    • Company issues FY25 revenue guidance including GAAP growth of 8.9% to 9.4%, adjusted currency-neutral growth of 8.8% to 9.3% and organic growth of 4.0% to 4.5%
    • Company issues FY25 adjusted diluted EPS guidance of $14.25 to $14.601, which reflects growth of about 10% at the midpoint

    FRANKLIN LAKES, N.J., Nov. 7, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced results for its fiscal 2024 fourth quarter and full year which ended September 30, 2024.

    "In FY24, our team advanced our strategy, continuing to shift our portfolio into higher-growth areas through new innovations and the acquisition of Edwards Lifesciences' Critical Care product group, while leveraging our BD Excellence system to exceed our margin expansion, earnings and cash flow goals," said Tom Polen, chairman, CEO and president of BD. "Our growth strategy remains focused on delivering solutions for our customers that leverage significant shifts in technology, like biologics, AI and automation, that are revolutionizing patient care. Combined with accelerated operational performance through BD Excellence and strong capital deployment, we are poised to deliver continued value creation for our shareholders." 

    1 BD does not attempt to provide reconciliations of forward-looking adjusted diluted EPS guidance to the comparable GAAP measure. See the discussion below under "Assumptions and Outlook for Full Year Fiscal 2025."

    Recent Business and Corporate Sustainability Highlights

    • The company completed the acquisition of Critical Care from Edwards Lifesciences, expanding BD's portfolio of smart connected care solutions with monitoring technologies, including advanced AI-enabled clinical decision tools. The combination of leading monitoring and infusion platforms enables future innovation opportunities for closed-loop monitoring and treatment by integrating combined company data sets and interoperability capabilities.
    • BD celebrated 75 years of U.S. manufacturing excellence in Nebraska where its Columbus site produces billions of vital medical supplies each year and where, for the first nine months of 2024, it boosted domestic syringe production to help improve supply continuity to health care providers and their patients.
    • BD Life Sciences:
      • The Integrated Diagnostic Solutions business unit announced Health Canada approval of the BD Onclarity™ HPV Assay for human papillomavirus (HPV) testing for the use with self-collected vaginal specimens at home. 
      • The Biosciences business unit announced a new robotics solution to automate and standardize single-cell research with the commercial launch of the first in a family of high-throughput, robotics-compatible reagent kits for use with the Hamilton Robotics Liquid-Handler, helping accelerate lab work leading to genomic sequencing.
    • BD Medical:
      • The Medication Delivery Solutions business unit announced:
        • The launch of the new BD® Intraosseous Vascular Access System, enabling access in seconds for rapid delivery of fluids or medication in critical emergency situations.
        • New data that shows BD MaxPlus™ and BD MaxZero™ Needle-free Connectors demonstrate better clinical outcomes with lower rate of central line bloodstream infections, fewer occlusions and cost savings.
      • The Medication Management Solutions business unit announced new data that reveals the use of advanced artificial intelligence in BD HealthSight™ Diversion Management software is highly effective in detecting indicators of controlled substance diversion in the operating room.
      • The Pharmaceutical Systems business unit announced:
        • The latest capacity expansion of the BD Neopak™ Glass Prefillable Syringe platform, a significant milestone that enables unprecedented large-scale production of advanced BD glass syringes to serve the growing market for biologic therapies.
        • The commercial release of the BD Neopak™ XtraFlow™ Glass Prefillable Syringe with features that enhance the injection experience for the next generation of biologics, expanding the usability of the BD Neopak™ platform.
        • These expansions add to BD's leadership in offering a broad range of injection solutions to enable delivery of treatments such as GLP-1s, antibodies and other next generation treatments for chronic disease.
    • Named a Best Place to Work for Disability Inclusion for the sixth consecutive year following its top score on the Disability Equality Index.
    • Named among the 100 Best Corporate Citizens of 2024 by 3BL, ranking second in the health care equipment and services industry.

    Fourth Quarter Fiscal 2024 Operating Results





    Three Months Ended

    September 30,



    Change



    Foreign Currency

    Neutral Change1



    Organic Revenue

    Change1,2

    (Millions of dollars, except per share amounts)



    2024



    2023







    Revenues



    $   5,437



    $   5,087



    6.9 %



    7.4 %



    6.2 %























    Reported Diluted Earnings per Share from Continuing Operations



    $     1.45



    $     0.53



    173.6 %



    198.1 %





    Adjusted Diluted Earnings per Share from Continuing Operations1



    $     3.81



    $     3.42



    11.4 %



    15.2 %







    1Represents a non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in the attached financial tables.

    2Organic Revenue growth denotes foreign currency neutral revenues further adjusted for the impact to revenues from acquisitions and divestitures during the first 12 months post-acquisition/divestiture.

    Geographic Results

    Revenues (Millions of dollars)



    Three Months Ended

    September 30,



    Reported Change



    Foreign Currency

    Neutral Change1





    2024



    2023





    United States



    $                3,117



    $                2,879



    8.3 %



    8.3 %



















    International



    $                2,320



    $                2,209



    5.1 %



    6.3 %



















    Total Revenues



    $                5,437



    $                5,087



    6.9 %



    7.4 %



    1Represents a non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in the attached financial tables.

    Segment Results

    Revenues (Millions of dollars)



    Three Months Ended

    September 30,



    Reported Change



    Foreign Currency

    Neutral Change1



    Organic Revenue

    Change1,2





    2024



    2023







    BD Medical



    $      2,837



    $      2,554



    11.1 %



    11.5 %



    8.6 %























    BD Life Sciences



    $      1,340



    $      1,330



    0.7 %



    1.4 %



    1.4 %























    BD Interventional



    $      1,260



    $      1,203



    4.7 %



    5.4 %



    6.6 %























    Total Revenues



    $      5,437



    $      5,087



    6.9 %



    7.4 %



    6.2 %



    1Represents a non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in the attached financial tables.

    2Organic Revenue growth denotes foreign currency neutral revenues further adjusted for the impact to revenues from acquisitions and divestitures during the first 12 months post-acquisition/divestiture. 

    The BD Medical segment includes the Medication Delivery Solutions (MDS), Medication Management Solutions (MMS) and Pharmaceutical Systems (PS) business units, and the Advanced Patient Monitoring (APM) business unit, which was formed upon the closing of the acquisition of Critical Care from Edwards Lifesciences. The segment's performance includes the revenues of APM from September 3, 2024 to September 30, 2024. BD Medical organic revenue growth was led by MMS.

    • MDS performance reflects strong volume growth across the portfolio with increased share in Vascular Access Management and hypodermic products.
    • MMS performance reflects high double-digit growth in Infusion driven by BD Alaris™ and higher utilization of infusion sets that was partially offset by the prior-year comparison in Dispensing Solutions.
    • PS performance reflects double-digit growth in Biologics, including GLP-1s, that was partially offset by expected transitory market dynamics including customer inventory de-stocking in anti-coagulants and vaccines.

    The BD Life Sciences segment includes the Integrated Diagnostic Solutions (IDS) and Biosciences (BDB) business units. BD Life Sciences revenue growth was driven by IDS.

    • IDS performance reflects strong growth in Specimen Management driven by broad volume strength, and double-digit growth in BD MAX™ IVD and BD COR™ that was partially offset by the prior-year comparison in Microbiology.
    • BDB performance reflects transitory market dynamics that resulted in lower market demand for research instruments partially offset by strong growth in clinical solutions that was driven by the FACSLyric™ Clinical Cell Analyzer and cancer reagents.

    The BD Interventional segment includes the Surgery, Peripheral Intervention (PI), and Urology & Critical Care (UCC) business units. BD Interventional organic revenue growth was driven by performance across the segment.

    • Surgery performance reflects double-digit growth in Infection Prevention and Phasix™ hernia resorbable scaffold that was partially offset by a tough prior-year comparison in Advanced Repair & Reconstruction. The unit's performance also reflects the impact from the divestiture of the Surgical Instrumentation platform.
    • PI performance reflects double-digit growth in the Peripheral Vascular Disease portfolio and strong growth in End Stage Kidney Disease that was partially offset by a decline in U.S. Oncology due to prior year distributor stocking.
    • UCC performance reflects strong double-digit growth in the PureWick™ franchise with continued adoption of both the Male and Female portfolios.

    Assumptions and Outlook for Full Year Fiscal 2025

    The company provided the following guidance with respect to fiscal 2025. GAAP revenue growth of 8.9% to 9.4% and currency-neutral adjusted revenue growth of 8.8% to 9.3% include the newly acquired APM business. The company's organic revenue growth guidance of 4.0% to 4.5% includes absorbing an impact about 125 basis points from an expected decline in revenues in China and Bioscience and Pharma market dynamics.



    Fiscal 2025 Guidance as of

    November 7, 2024

    GAAP Revenues

    ~$21.9 to $22.1 billion

    GAAP Revenue Growth

    8.9% to 9.4%

    Adjusted Revenue Growth (FXN)

    8.8% to 9.3%

    Organic Revenue Growth (FXN)

    4.0% to 4.5%





    Adjusted Diluted EPS

    $14.25 to $14.60

    Adjusted Diluted EPS Growth

    ~8.5% to 11.0%

    BD's outlook for fiscal 2025 reflects numerous assumptions about many factors that could affect its business, based on the information management has reviewed as of this date. Management will discuss its outlook and several of its assumptions on its fourth fiscal quarter earnings call. 

    The company's expected adjusted diluted EPS for fiscal 2025 excludes potential charges or gains that may be recorded during the fiscal year, such as, among other things, the non-cash amortization of intangible assets, acquisition-related charges, spin-related costs, and certain tax matters. BD does not attempt to provide reconciliations of forward-looking adjusted diluted non-GAAP EPS guidance to the comparable GAAP measure because the impact and timing of these potential charges or gains is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, the company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a material impact on GAAP measures of BD's financial performance. We also present our estimated adjusted revenue growth and organic revenue growth for our 2025 fiscal year after adjusting for the illustrative impact of foreign currency translation. BD believes that this adjustment allows investors to better evaluate BD's anticipated underlying earnings performance for our 2025 fiscal year in relation to our underlying 2024 fiscal year performance.

    Conference Call and Presentation Materials

    BD will host an audio webcast today for the public, investors, analysts, and news media to discuss its fourth quarter results. The audio webcast will be broadcast live on BD's website, www.bd.com/investors at 8 a.m. (ET) Thursday, November 7, 2024. Accompanying slides will be available on BD's website, www.bd.com/investors at approximately 6:30 a.m. (ET). The conference call will be available for replay on BD's website, www.bd.com/investors. Alternatively, you can dial into the replay at 800-839-1337 (domestic) and 402-220-0489 (international) through the close of business on Thursday, November 14, 2024. A confirmation number is not needed to access the replay.

    Non-GAAP Financial Measures/Financial Tables

    This news release contains certain non-GAAP financial measures. These include adjusted revenues, revenue growth rates on a currency-neutral, adjusted, and organic basis, adjusted diluted earnings per share from continuing operations, and free cash flow. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States. BD management believes that the use of non-GAAP measures to adjust for items that are considered by management to be outside of BD's underlying operational results or that affect period to period comparability helps investors to gain a better understanding of our performance year-over-year, to analyze underlying trends in our businesses, to analyze our operating results, and to understand future prospects. Management uses these non-GAAP financial measures to measure and forecast the company's performance, especially when comparing such results to previous periods or forecasts. We believe presenting such adjusted metrics provides investors with greater transparency to the information used by BD management for its operational decision-making and for comparison to other companies within the medical technology industry. Although BD's management believes non-GAAP results are useful in evaluating the performance of its business, its reliance on these measures is limited since items excluded from such measures may have a material impact on BD's net income, earnings per share or cash flows calculated in accordance with GAAP. Therefore, management typically uses non-GAAP results in conjunction with GAAP results to address these limitations. BD strongly encourages investors to review its consolidated financial statements and publicly filed reports in their entirety and cautions investors that the non-GAAP measures used by BD may differ from similar measures used by other companies, even when similar terms are used to identify such measures. Non-GAAP measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.

    We present adjusted revenues for the full fiscal year 2024 after eliminating the recognition of accruals resulting from recent developments relating to the Italian government medical device pay back legislation, as well as another legal matter, which substantially relate to years prior to the current fiscal year, because we believe these items affect the comparability of the periods presented to prior periods.

    We also present adjusted diluted earnings per share from continuing operations for the fourth quarter and full fiscal year 2024, and the corresponding prior periods, after eliminating items we believe are not part of our ordinary operations and affect the comparability of the periods presented. Adjusted diluted earnings per share from continuing operations includes adjustments for the impact of purchase accounting adjustments, integration and restructuring costs, transaction and financing costs, spin-off related costs, certain regulatory costs, certain product remediation costs, certain legal matters, certain investment gains and losses, certain asset impairment charges, and certain pension settlement costs. In particular, current and prior-year adjusted diluted earnings per share from continuing operations results exclude European regulatory initiative-related costs, which represent costs incurred to develop processes and systems to establish initial compliance with the European Union Medical Device Regulation and the European Union In Vitro Diagnostic Medical Device Regulation (collectively, the "New EU Medical Devices Regulations"), which represent a significant, unusual change to the existing regulatory framework. We consider the excluded European regulatory initiative-related costs to be duplicative of previously incurred costs and/or one-off costs related to establishing initial compliance with such regulatory regimes, and in each case are limited to a specific period of time. These expenses relate to establishing initial compliance with the New EU Medical Devices Regulations and include the cost of labor, other services and consulting (in particular, research and development and clinical trials) and supplies, travel and other miscellaneous costs. These costs were recorded in Cost of products sold and Research and development expense.

    We also present revenue growth rates for the fourth quarter and full fiscal year 2024 over the corresponding prior periods on a currency-neutral basis after eliminating the effect of foreign currency translation, where applicable. We also show the growth in adjusted diluted earnings per share from continuing operations compared to the prior year periods after eliminating the impact of foreign currency translation to further enable investors to evaluate BD's underlying earnings performance compared to the prior periods. We calculate foreign currency-neutral percentages by converting our current-period local currency financial results using the prior period foreign currency exchange rates and comparing these adjusted amounts to our current-period results. As exchange rates are an important factor in understanding period-to-period comparisons, we believe the presentation of results on a foreign currency-neutral basis in addition to reported results helps improve investors' ability to understand our operating results and evaluate our performance in comparison to the prior periods. 

    We also present free cash flow for the full fiscal year 2024 over the corresponding prior period, which is net cash provided by continuing operating activities less capital expenditures, to provide a view of the Company's ability to generate cash for use in acquisitions and other investing and financing activities. Free cash flow is not a measure of cash available for discretionary expenditures given that we have certain non-discretionary obligations such as debt service that are not deducted from the measure. We believe the presentation of results of free cash flow in addition to reported results helps improve investors' ability to understand our operating results and evaluate our performance in comparison to the prior period.

    Reconciliations of these and other non-GAAP measures to the comparable GAAP measures are included in the attached financial tables. Within the attached financial tables presented, certain columns and rows may not add due to the use of rounded numbers. Percentages and earnings per share amounts presented are calculated from the underlying amounts.

    About BD

    BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and on X (formerly known as Twitter) @BDandCo.

    ***

    This press release and accompanying audio webcast on November 7, 2024 contain certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's future prospects and performance, including, but not limited to, future revenues, margins, earnings per share, leverage targets and capital deployment. All such statements are based upon current expectations and assumptions of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to such forward-looking statements, a number of factors could cause actual results to vary materially. These factors include, but are not limited to, risks relating to macroeconomic conditions and their impact on our operations and healthcare spending generally, including any impact of disruptions in the global transportation networks or other aspects of our supply chain on our ability to source raw materials, components and energy sources needed to produce our products, labor constraints or disputes, inflationary pressures, currency rate fluctuations, and increased interest rates and borrowing costs; conditions in international markets, including geopolitical developments such as the evolving situations in Russia and Ukraine, the Middle East and Asia, which could adversely impact our operations; competitive factors including technological advances and new products or novel medical therapies introduced by competitors; product efficacy or safety concerns or non-compliance with applicable regulatory requirements (such as non-compliance of our products with registration requirements resulting from modifications to such products, or other factors, including with respect to BD Alaris™ pumps and related sets and BD Vacutainer™) resulting in product recalls, lost revenue or other actions being taken with respect to products in the field or the ability to continue selling new products to customers; changes to legislation or regulations impacting the U.S. or foreign healthcare systems, changes in medical practices or in patient preferences, potential cuts in governmental research or other healthcare spending, or governmental or private measures to contain healthcare costs, such as China's volume-based procurement tender process or changes in pricing and reimbursement policies, which could result in reduced demand for our products or downward pricing pressure; the adverse impact on our business or products of past, current or future information and technology system disruptions, breaches or breakdowns, including through cyberattacks, ransom attacks or cyber-intrusion, and any investigations, legal proceedings, liability, expense or reputational damage arising in connection with any such events; increased labor costs and labor shortages or disputes; new or changing laws and regulations impacting our business (including the imposition of tariffs, sanctions, changes in tax laws, new environmental laws and regulations (such as those related to climate change or materials of concern), new cybersecurity, artificial intelligence or privacy laws, or changes in laws impacting international trade or anti-corruption and bribery, or changes in reporting requirements or enforcement practices with respect to such laws; our suppliers' ability to provide products needed for our operations and BD's ability to maintain favorable supplier arrangements and relationships; increases in energy costs and their effect on, among other things, the cost of producing BD's products; adverse changes in regional, national or foreign economic conditions, including any impact on our ability to access credit markets and finance our operations; risks relating to our overall indebtedness; the possible impact of public health crises on our business and the global healthcare system, which could decrease demand for our products, disrupt our operations or the operations of our customers and companies within our supply chain, or increase transportation costs; interruptions in our manufacturing or sterilization processes or those of our third-party providers, including any restrictions placed on the use of ethylene oxide for sterilization; pricing and market pressures; difficulties inherent in product development, delays in product introductions and uncertainty of market acceptance of new products; the overall timing of the replacement or remediation of the BD Alaris™ Infusion System and return to market in the U.S., which may be impacted by, among other things, customer readiness, supply continuity and our continued engagement with the FDA; our ability to achieve our projected level or mix of product sales; our ability to successfully integrate any businesses we acquire; uncertainties of litigation, investigations, subpoenas, settlements, fines, penalties and/or other sanctions (as described in BD's filings with the Securities and Exchange Commission ("SEC")); and the issuance of new or revised accounting standards, as well as other factors discussed in BD's filings with the SEC. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

    Contacts:

    Investors: Adam Reiffe, Sr. Director, Investor Relations - 201-847-6927

    Media: Troy Kirkpatrick, VP, Public Relations - 858-617-2361

    BECTON DICKINSON AND COMPANY

    CONDENSED CONSOLIDATED INCOME STATEMENTS

    (Unaudited; Amounts in millions, except share and per share data)

     





    Three Months Ended September 30,





    2024



    2023



    % Change

    REVENUES



    $

    5,437





    $

    5,087





    6.9

















    Cost of products sold



    2,922





    3,386





    (13.7)



    Selling and administrative expense



    1,256





    1,137





    10.4



    Research and development expense



    302





    281





    7.7



    Integration, restructuring and transaction expense



    170





    138





    23.2



    Other operating expense (income), net



    137





    (203)





    167.3



    TOTAL OPERATING COSTS AND EXPENSES



    4,787





    4,738





    1.0



    OPERATING INCOME



    650





    349





    86.4

















    Interest expense



    (155)





    (114)





    36.3



    Interest income



    56





    9





    493.7



    Other expense, net



    (9)





    (63)





    85.1



    INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES



    542





    181





    198.8



    Income tax provision



    121





    27





    342.5



    NET INCOME FROM CONTINUING OPERATIONS



    421





    154





    173.2



    Loss from Discontinued Operations, Net of Tax



    —





    (46)





    100.0



    NET INCOME APPLICABLE TO COMMON SHAREHOLDERS



    $

    421





    $

    108





    290.1

















    BASIC EARNINGS PER SHARE













    Income from Continuing Operations



    1.45





    0.53





    173.6



    Loss from Discontinued Operations



    —





    (0.16)





    100.0



    Basic Earnings per Share



    $

    1.45





    $

    0.37





    291.9

















    DILUTED EARNINGS PER SHARE













    Income from Continuing Operations



    1.45





    0.53





    173.6



    Loss from Discontinued Operations



    —





    (0.16)





    100.0



    Diluted Earnings per Share



    $

    1.45





    $

    0.37





    291.9

















    AVERAGE SHARES OUTSTANDING (in thousands)













    Basic



    289,607



    290,590





    Diluted



    290,602



    292,701





     

    BECTON DICKINSON AND COMPANY

    CONDENSED CONSOLIDATED INCOME STATEMENTS

    (Unaudited; Amounts in millions, except share and per share data)

     





    Twelve Months Ended September 30,





    2024



    2023



    % Change

    REVENUES



    $

    20,178





    $

    19,372





    4.2

















    Cost of products sold



    11,025





    11,202





    (1.6)



    Selling and administrative expense



    4,857





    4,719





    2.9



    Research and development expense



    1,190





    1,237





    (3.8)



    Integration, restructuring and transaction expense



    458





    313





    46.2



    Other operating expense (income), net



    222





    (210)





    206.0



    TOTAL OPERATING COSTS AND EXPENSES



    17,752





    17,261





    2.8



    OPERATING INCOME



    2,425





    2,111





    14.9

















    Interest expense



    (528)





    (452)





    16.7



    Interest income



    163





    49





    233.5



    Other expense, net



    (28)





    (46)





    38.3



    INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES



    2,033





    1,662





    22.3



    Income tax provision



    307





    132





    133.0



    NET INCOME FROM CONTINUING OPERATIONS



    1,726





    1,530





    12.8



    Loss from Discontinued Operations, Net of Tax



    —





    (46)





    100.0



    NET INCOME



    1,726





    1,484





    16.3



    Preferred stock dividends



    —





    (60)





    (100.0)



    NET INCOME APPLICABLE TO COMMON SHAREHOLDERS



    $

    1,726





    $

    1,424





    21.2

















    BASIC EARNINGS PER SHARE













    Income from Continuing Operations



    5.96





    5.14





    16.0



    Loss from Discontinued Operations



    —





    (0.16)





    100.0



    Basic Earnings per Share



    $

    5.96





    $

    4.97





    19.9

















    DILUTED EARNINGS PER SHARE













    Income from Continuing Operations



    5.93





    5.10





    16.3



    Loss from Discontinued Operations



    —





    (0.16)





    100.0



    Diluted Earnings per Share



    $

    5.93





    $

    4.94





    20.0

















    AVERAGE SHARES OUTSTANDING (in thousands)













    Basic



    289,763



    286,282





    Diluted



    291,009



    288,392





     

    BECTON DICKINSON AND COMPANY

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (Unaudited; Amounts in millions)

     





    September 30, 2024



    September 30, 2023

    ASSETS









    Cash and equivalents



    $

    1,717





    $

    1,416



    Restricted cash



    139





    65



    Short-term investments



    445





    8



    Trade receivables, net



    3,033





    2,534



    Inventories



    3,843





    3,273



    Prepaid expenses and other



    1,292





    1,380



    TOTAL CURRENT ASSETS



    10,468





    8,676



    Property, plant and equipment, net



    6,821





    6,557



    Goodwill and other intangibles, net



    37,383





    35,469



    Other assets



    2,615





    2,078



    TOTAL ASSETS



    $

    57,286





    $

    52,780



    LIABILITIES AND SHAREHOLDERS' EQUITY









    Current debt obligations



    $

    2,170





    $

    1,141



    Other current liabilities



    6,777





    5,500



    Long-term debt



    17,940





    14,738



    Long-term employee benefit obligations



    942





    1,023



    Deferred income taxes and other liabilities



    3,546





    4,582



    Shareholders' equity



    25,911





    25,796



    TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY



    $

    57,286





    $

    52,780



     

    BECTON DICKINSON AND COMPANY

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (Unaudited; Amounts in millions)

     









    Twelve Months Ended September 30,





    2024



    2023

    OPERATING ACTIVITIES









    Net income



    $

    1,726





    $

    1,484



    Less: Loss from discontinued operations, net of tax



    —





    (46)



    Income from continuing operations, net of tax



    1,726





    1,530



    Depreciation and amortization



    2,286





    2,288



    Change in operating assets and liabilities and other, net



    (168)





    (828)



    NET CASH PROVIDED BY CONTINUING OPERATING ACTIVITIES



    3,844





    2,990



    INVESTING ACTIVITIES









    Capital expenditures



    (725)





    (874)



    Acquisitions, net of cash acquired



    (3,924)





    —



    Proceeds from divestiture, net



    —





    540



    Purchases of investments, net



    (421)





    —



    Other, net



    (444)





    (382)



    NET CASH USED FOR CONTINUING INVESTING ACTIVITIES



    (5,514)





    (716)



    FINANCING ACTIVITIES









    Change in short-term debt



    400





    (230)



    Proceeds from long-term debt



    4,517





    1,662



    Payments of debt



    (1,142)





    (2,155)



    Repurchases of common stock



    (500)





    —



    Dividends paid



    (1,100)





    (1,114)



    Other, net



    (89)





    (120)



    NET CASH PROVIDED BY (USED FOR) CONTINUING FINANCING ACTIVITIES



    2,087





    (1,956)



    Net cash used for operating activities of discontinued operations



    (46)





    (1)



    Effect of exchange rate changes on cash and equivalents and restricted cash



    4





    5



    NET INCREASE IN CASH AND EQUIVALENTS AND RESTRICTED CASH



    375





    322



    OPENING CASH AND EQUIVALENTS AND RESTRICTED CASH



    1,481





    1,159



    CLOSING CASH AND EQUIVALENTS AND RESTRICTED CASH



    $

    1,856





    $

    1,481



     

    BECTON DICKINSON AND COMPANY

    SUPPLEMENTAL REVENUE INFORMATION

    REVENUES BY BUSINESS SEGMENTS AND UNITS - UNITED STATES

    Three Months Ended September 30,

    (Unaudited; Amounts in millions)



















    A 



    B 



    C=(A-B)/B





    2024



    2023



    % Change

    BD MEDICAL













    Medication Delivery Solutions



    $

    689





    $

    656





    5.0



    Medication Management Solutions



    744





    602





    23.6



    Pharmaceutical Systems



    187





    188





    (0.4)



    Advanced Patient Monitoring



    47





    —





    NM



    TOTAL



    $

    1,667





    $

    1,447





    15.3

















    BD LIFE SCIENCES













    Integrated Diagnostic Solutions



    $

    448





    $

    447





    0.2



    Biosciences



    151





    159





    (5.2)



    TOTAL



    $

    598





    $

    606





    (1.2)

















    BD INTERVENTIONAL













    Surgery



    $

    279





    $

    279





    (0.1)



    Peripheral Intervention



    267





    268





    (0.4)



    Urology and Critical Care



    306





    279





    9.4



    TOTAL



    $

    851





    $

    826





    3.0

















    TOTAL UNITED STATES



    $

    3,117





    $

    2,879





    8.3





    "NM" denotes that the percentage change is not meaningful.

     

    BECTON DICKINSON AND COMPANY

    SUPPLEMENTAL REVENUE INFORMATION

    REVENUES BY BUSINESS SEGMENTS AND UNITS - INTERNATIONAL

    Three Months Ended September 30, (continued)

    (Unaudited; Amounts in millions)

























    D=(A-B)/B



    E=(A-B-C)/B





    A



    B



    C



    % Change





    2024



    2023



    FX Impact



    Reported



    FXN

    BD MEDICAL





















    Medication Delivery Solutions



    $

    458





    $

    442





    $

    (8)





    3.6





    5.5



    Medication Management Solutions



    195





    194





    (1)





    0.3





    0.6



    Pharmaceutical Systems



    490





    471





    (2)





    4.0





    4.4



    Advanced Patient Monitoring



    27





    —





    —





    NM





    NM



    TOTAL



    $

    1,170





    $

    1,107





    $

    (11)





    5.6





    6.6

























    BD LIFE SCIENCES





















    Integrated Diagnostic Solutions



    $

    495





    $

    479





    $

    (7)





    3.4





    4.9



    Biosciences



    247





    246





    (1)





    0.4





    1.0



    TOTAL



    $

    742





    $

    724





    $

    (9)





    2.4





    3.6

























    BD INTERVENTIONAL





















    Surgery



    $

    89





    $

    87





    $

    (2)





    3.2





    5.0



    Peripheral Intervention



    235





    214





    (4)





    9.7





    11.5



    Urology and Critical Care



    84





    76





    (2)





    11.0





    13.8



    TOTAL



    $

    409





    $

    377





    $

    (8)





    8.5





    10.5

























    TOTAL INTERNATIONAL



    $

    2,320





    $

    2,209





    $

    (27)





    5.1





    6.3





    "NM" denotes that the percentage change is not meaningful.

     

    BECTON DICKINSON AND COMPANY

    SUPPLEMENTAL REVENUE INFORMATION

    REVENUES BY BUSINESS SEGMENTS AND UNITS - TOTAL

    Three Months Ended September 30, (continued)

    (Unaudited; Amounts in millions)







































    D=(A-B)/B



    E=(A-B-C)/B





    A



    B



    C



    % Change





    2024



    2023



    FX Impact



    Reported



    FXN

    BD MEDICAL





















    Medication Delivery Solutions



    $

    1,147





    $

    1,098





    $

    (8)





    4.4





    5.2



    Medication Management Solutions



    939





    796





    (1)





    17.9





    18.0



    Pharmaceutical Systems



    677





    659





    (2)





    2.7





    3.0



    Advanced Patient Monitoring



    74





    —





    —





    NM





    NM



    TOTAL



    $

    2,837





    $

    2,554





    $

    (11)





    11.1





    11.5

























    BD LIFE SCIENCES





















    Integrated Diagnostic Solutions



    $

    943





    $

    926





    $

    (7)





    1.8





    2.6



    Biosciences



    397





    405





    (1)





    (1.8)





    (1.4)



    TOTAL



    $

    1,340





    $

    1,330





    $

    (9)





    0.7





    1.4

























    BD INTERVENTIONAL





















    Surgery



    $

    368





    $

    366





    $

    (2)





    0.7





    1.1



    Peripheral Intervention



    502





    482





    (4)





    4.1





    4.9



    Urology and Critical Care



    390





    355





    (2)





    9.7





    10.3



    TOTAL



    $

    1,260





    $

    1,203





    $

    (8)





    4.7





    5.4

























    TOTAL REVENUES



    $

    5,437





    $

    5,087





    $

    (27)





    6.9





    7.4





    "NM" denotes that the percentage change is not meaningful.

     

    BECTON DICKINSON AND COMPANY

    SUPPLEMENTAL REVENUE INFORMATION

    REVENUES BY BUSINESS SEGMENTS AND UNITS - UNITED STATES

    Twelve Months Ended September 30,

    (Unaudited; Amounts in millions)



















    A



    B



    C=(A-B)/B





    2024



    2023



    % Change

    BD MEDICAL













    Medication Delivery Solutions



    $

    2,661





    $

    2,519





    5.6



    Medication Management Solutions



    2,627





    2,303





    14.1



    Pharmaceutical Systems



    629





    666





    (5.5)



    Advanced Patient Monitoring



    47





    —





    NM



    TOTAL



    $

    5,964





    $

    5,488





    8.7

















    BD LIFE SCIENCES













    Integrated Diagnostic Solutions



    $

    1,733





    $

    1,774





    (2.3)



    Biosciences



    577





    603





    (4.4)



    TOTAL



    $

    2,310





    $

    2,377





    (2.8)

















    BD INTERVENTIONAL













    Surgery



    $

    1,130





    $

    1,159





    (2.5)



    Peripheral Intervention



    1,029





    1,016





    1.3



    Urology and Critical Care



    1,236





    1,073





    15.2



    TOTAL



    $

    3,394





    $

    3,247





    4.5

















    Other(1)



    $

    (6)





    $

    —





    NM

















    TOTAL UNITED STATES



    $

    11,663





    $

    11,113





    4.9

















    "NM" denotes that the percentage change is not meaningful.

    (1)

    Represents an accrual resulting from a legal matter and which substantially relates to years prior to the current fiscal year. This amount was not allocated to our reportable segments.

     

    BECTON DICKINSON AND COMPANY

    SUPPLEMENTAL REVENUE INFORMATION

    REVENUES BY BUSINESS SEGMENTS AND UNITS - INTERNATIONAL

    Twelve Months Ended September 30, (continued)

    (Unaudited; Amounts in millions)







































    D=(A-B)/B



    E=(A-B-C)/B





    A



    B



    C



    % Change





    2024



    2023



    FX Impact



    Reported



    FXN

    BD MEDICAL





















    Medication Delivery Solutions



    $

    1,768





    $

    1,774





    $

    (4)





    (0.3)





    (0.1)



    Medication Management Solutions



    670





    677





    5





    (1.0)





    (1.7)



    Pharmaceutical Systems



    1,644





    1,563





    3





    5.2





    5.0



    Advanced Patient Monitoring



    27





    —





    —





    NM





    NM



    TOTAL



    $

    4,110





    $

    4,014





    $

    4





    2.4





    2.3

























    BD LIFE SCIENCES





















    Integrated Diagnostic Solutions



    $

    1,946





    $

    1,850





    $

    (2)





    5.2





    5.3



    Biosciences



    935





    906





    1





    3.3





    3.2



    TOTAL



    $

    2,881





    $

    2,756





    $

    (1)





    4.6





    4.6

























    BD INTERVENTIONAL





















    Surgery



    $

    363





    $

    338





    $

    (2)





    7.2





    7.8



    Peripheral Intervention



    904





    849





    (9)





    6.5





    7.6



    Urology and Critical Care



    319





    301





    (7)





    5.7





    7.9



    TOTAL



    $

    1,586





    $

    1,489





    $

    (18)





    6.5





    7.7

























    Other(1)



    $

    (62)





    $

    —





    $

    —





    NM





    NM

























    TOTAL INTERNATIONAL



    $

    8,515





    $

    8,258





    $

    (14)





    3.1





    3.3

























    "NM" denotes that the percentage change is not meaningful.

    (1)

    Represents the recognition of an accrual resulting from recent developments relating to the Italian government medical device pay back legislation and which substantially relates to years prior to the current fiscal year. This amount was not allocated to our reportable segments.

     

    BECTON DICKINSON AND COMPANY

    SUPPLEMENTAL REVENUE INFORMATION

    REVENUES BY BUSINESS SEGMENTS AND UNITS - TOTAL

    Twelve Months Ended September 30, (continued)

    (Unaudited; Amounts in millions)







































    D=(A-B)/B



    E=(A-B-C)/B





    A



    B



    C



    % Change





    2024



    2023



    FX Impact



    Reported



    FXN

    BD MEDICAL





















    Medication Delivery Solutions



    $

    4,429





    $

    4,293





    $

    (4)





    3.2





    3.3



    Medication Management Solutions



    3,297





    2,980





    5





    10.7





    10.5



    Pharmaceutical Systems



    2,273





    2,229





    3





    2.0





    1.8



    Advanced Patient Monitoring



    74





    —





    —





    NM





    NM



    TOTAL



    $

    10,074





    $

    9,502





    $

    4





    6.0





    6.0

























    BD LIFE SCIENCES





















    Integrated Diagnostic Solutions



    $

    3,679





    $

    3,624





    $

    (2)





    1.5





    1.6



    Biosciences



    1,512





    1,509





    1





    0.2





    0.2



    TOTAL



    $

    5,191





    $

    5,133





    $

    (1)





    1.1





    1.1

























    BD INTERVENTIONAL





















    Surgery



    $

    1,492





    $

    1,497





    $

    (2)





    (0.3)





    (0.2)



    Peripheral Intervention



    1,933





    1,865





    (9)





    3.7





    4.1



    Urology and Critical Care



    1,554





    1,374





    (7)





    13.1





    13.6



    TOTAL



    $

    4,980





    $

    4,736





    $

    (18)





    5.1





    5.5

























    Other(1)



    $

    (67)





    $

    —





    $

    —





    NM





    NM

























    TOTAL REVENUES



    $

    20,178





    $

    19,372





    $

    (14)





    4.2





    4.2





    "NM" denotes that the percentage change is not meaningful.

    (1)

    Represents the recognition of accruals resulting from recent developments relating to the Italian government medical device pay back legislation, as well as another legal matter, and which substantially relate to years prior to the current fiscal year. Such amounts were not allocated to our reportable segments.

     

    BECTON DICKINSON AND COMPANY

    SUPPLEMENTAL REVENUE INFORMATION

    RECONCILIATION OF REPORTED REVENUE CHANGE TO ORGANIC REVENUE CHANGE

    Three Months Ended September 30,

    (Unaudited; Amounts in millions)



































    D = (A-B)/B



    E=(A-B-C)/B





    A



    B



    C



    % Change





    2024



    2023



    FX Impact



    Reported



    FXN

    TOTAL REVENUES



    $

    5,437





    $

    5,087





    $

    (27)





    6.9





    7.4



    Less: Inorganic revenue adjustment (1)



    74





    14





    —





    444.6





    444.6



    Organic Revenue



    $

    5,363





    $

    5,074





    $

    (27)





    5.7





    6.2

























    BD MEDICAL REVENUES



    $

    2,837





    $

    2,554





    $

    (11)





    11.1





    11.5



    Less: Inorganic revenue adjustment (1)



    74





    —





    —





    NM





    NM



    BD Medical Organic Revenue



    $

    2,763





    $

    2,554





    $

    (11)





    8.2





    8.6

























    BD INTERVENTIONAL REVENUES



    $

    1,260





    $

    1,203





    $

    (8)





    4.7





    5.4



    Less: Inorganic revenue adjustment (1)



    —





    14





    —





    (100.0)





    (100.0)



    BD Interventional Organic Revenue



    $

    1,260





    $

    1,190





    $

    (8)





    5.9





    6.6





    "NM" denotes that the percentage change is not meaningful.

    (1)

    Inorganic revenue adjustment is defined as the amount of incremental revenue attributable to acquisitions and the revenue decline attributable to divestitures during the first 12 months post-acquisition/divestiture. Acquisitions include: Edwards Lifesciences' Critical Care Product Group, which was renamed as BD Advanced Patient Monitoring, in the Medical Segment. Divestitures include: the sale of the Surgical Instrumentation platform in the Interventional segment.

     

    BECTON DICKINSON AND COMPANY

    SUPPLEMENTAL REVENUE INFORMATION

    RECONCILIATION OF REPORTED REVENUE CHANGE TO ADJUSTED REVENUE CHANGE TO ORGANIC REVENUE CHANGE

    Twelve Months Ended September 30,

    (Unaudited; Amounts in millions)







































    D=(A-B)/B



    E=(A-B-C)/B





    A



    B



    C



    % Change





    2024



    2023



    FX Impact



    Reported



    FXN

    TOTAL REVENUES



    $

    20,178





    $

    19,372





    $

    (14)





    4.2





    4.2



    Add: Reduction for government legislative and legal matters(1)



    67





    —





    —





    NM





    NM



    Adjusted Total Revenues



    $

    20,245





    $

    19,372





    $

    (14)





    4.5





    4.6



    Less: Inorganic revenue adjustment (2)



    $

    74





    $

    140





    $

    —





    (46.9)





    (46.9)



    Organic Revenue



    $

    20,171





    $

    19,232





    $

    (14)





    4.9





    5.0





    "NM" denotes that the percentage change is not meaningful.

    (1)

    Represents the recognition of accruals resulting from recent developments relating to the Italian government medical device pay back legislation, as well as another legal matter, and which substantially relate to years prior to the current fiscal year.

    (2)

    Inorganic revenue adjustment is defined as the amount of incremental revenue attributable to acquisitions and the revenue decline attributable to divestitures during the first 12 months post-acquisition/divestiture. Acquisitions include: Edwards Lifesciences' Critical Care Product Group, which was renamed as BD Advanced Patient Monitoring, in the Medical Segment. Divestitures include: the sale of the Surgical Instrumentation platform in the Interventional segment.

     

    BECTON DICKINSON AND COMPANY

    SUPPLEMENTAL INFORMATION

    RECONCILIATION FROM NET CASH PROVIDED BY CONTINUING OPERATING ACTIVITIES TO FREE CASH FLOW

    Twelve Months Ended September 30,

    (Unaudited; Amounts in millions)























    A



    B



    C=A-B



    D=C/B





    2024



    2023



    Change



    % Change

    Net Cash Provided by Continuing Operating Activities



    $

    3,844





    $

    2,990





    $

    854





    28.5

    %

    Capital Expenditures



    (725)





    (874)





    149





    (17.0)

    %

    Free Cash Flow



    $

    3,119





    $

    2,116





    $

    1,002





    47.4

    %

     

    BECTON DICKINSON AND COMPANY

    SUPPLEMENTAL INFORMATION

    RECONCILIATION OF REPORTED DILUTED EPS TO ADJUSTED DILUTED EPS

    (Unaudited)































    Three Months Ended September 30,



    2024



    2023



    Change



    FX Impact



    FXN

    Change



    Change %



    FXN

    Change %

    Reported Diluted Earnings per Share from Continuing Operations

    $

    1.45





    $

    0.53





    $

    0.92





    $

    (0.13)





    $

    1.05





    173.6 %



    198.1 %

    Purchase accounting adjustments ($427 million and $363 million pre-tax, respectively) (1)

    1.47





    1.24









    —















    Integration costs ($6 million and $12 million pre-tax, respectively) (2)

    0.02





    0.04









    —















    Restructuring costs ($125 million and $119 million pre-tax, respectively) (2)

    0.43





    0.41









    —















    Transaction Costs ($39 million pre-tax) (3)

    0.13





    —









    —















    Financing Costs (($6) million pre-tax) (3)

    (0.02)





    —









    —















    Separation-related items ($6 million and $4 million pre-tax, respectively) (4)

    0.02





    0.02









    —















    European regulatory initiative-related costs ($32 million and $36 million pre-tax, respectively) (5)

    0.11





    0.12









    —















    Product, litigation, and other items ($149 million and $458 million pre-tax, respectively) (6)

    0.51





    1.56









    —















    Tax impact of specified items and other tax related (($93) million and ($146) million, respectively)

    (0.32)





    (0.50)









    —















    Adjusted Diluted Earnings per Share from Continuing Operations

    $

    3.81





    $

    3.42





    $

    0.39





    $

    (0.13)





    $

    0.52





    11.4 %



    15.2 %





    (1)

    Includes amortization and other adjustments related to the purchase accounting for acquisitions.

    (2)

    Represents costs associated with integration and restructuring activities.

    (3)

    Represents transaction costs and financing impacts associated with the acquisition of Edwards Lifesciences' Critical Care Product Group. The transaction costs are recorded in Integration, restructuring and transaction expense and the financing impacts are recorded in Interest income and Interest expense.

    (4)

    Represents costs recorded to Other operating expense (income), net incurred in connection with the separation of BD's former Diabetes Care business.

    (5)

    Represents costs incurred to develop processes and systems to establish initial compliance with the European Union Medical Device Regulation and the European Union In Vitro Diagnostic Medical Device Regulation, which represent a significant, unusual change to the existing regulatory framework. We consider these costs to be duplicative of previously incurred costs and/or one-off costs, which are limited to a specific period of time. These expenses, which are recorded in Cost of products sold and Research and development expense, include the cost of labor, other services and consulting (in particular, research and development and clinical trials) and supplies, travel and other miscellaneous costs.

    (6)

    Includes certain (income) expense items which are not part of ordinary operations and affect the comparability of the periods presented. Such items may include certain product remediation costs, certain legal matters, certain investment gains and losses, certain asset impairment charges, and certain pension settlement costs. The amount in 2024 reflects charges to Other operating expense (income), net related to legal matters, including a $125 million charge to accrue an estimated liability for the SEC investigation with respect to, among other things, certain reporting issues involving BD Alaris™ infusion pumps included in SEC disclosures prior to 2021, based on discussions with the SEC with respect to a potential resolution of this matter. The Company cannot anticipate the timing, scope, outcome or ultimate impact of the SEC investigation, financial or otherwise, including but not limited to what actions the SEC might pursue against the Company and/or individuals. As a result, the ultimate resolution is unknown at this time, and it is possible that the amount of the Company's liability could significantly exceed its currently accrued amount. The amount in 2023 includes a charge of $563 million to adjust the estimate of future product remediation costs to Cost of products sold and a charge of $55 million related to pension settlement costs to Other expense, net. The amount in 2023 also includes a gain of $268 million related to the sale of our Surgical Instrumentation platform recorded to Other operating expense (income), net.

     

    BECTON DICKINSON AND COMPANY

    SUPPLEMENTAL INFORMATION

    RECONCILIATION OF REPORTED DILUTED EPS TO ADJUSTED DILUTED EPS

    (Unaudited)































    Twelve Months Ended September 30,



    2024



    2023



    Change



    FX Impact



    FXN

    Change



    Change %



    FXN

    Change %

    Reported Diluted Earnings per Share from Continuing Operations

    $

    5.93





    $

    5.10





    $

    0.83





    $

    (0.56)





    $

    1.39





    16.3

    %



    27.3

    %

    Purchase accounting adjustments ($1.503 billion and $1.434 billion pre-tax, respectively) (1)

    5.16





    4.97









    —















    Integration costs ($23 million and $67 million pre-tax, respectively) (2)

    0.08





    0.23









    —















    Restructuring costs ($387 million and $239 million pre-tax, respectively) (2)

    1.33





    0.83









    0.01















    Transaction Costs ($48 million pre-tax) (3)

    0.17





    —









    —















    Financing Costs (($8) million pre-tax) (3)

    (0.03)





    —









    —















    Separation-related items ($13 million and $14 million pre-tax, respectively) (4)

    0.05





    0.05









    —















    European regulatory initiative-related costs ($104 million and $139 million pre-tax, respectively) (5)

    0.36





    0.48









    —















    Product, litigation, and other items ($318 million and $554 million pre-tax, respectively) (6)

    1.09





    1.92









    —















    Tax impact of specified items and other tax related (($290) million and ($399) million, respectively)

    (1.00)





    (1.38)









    —















    Adjusted Diluted Earnings per Share from Continuing Operations

    $

    13.14





    $

    12.21





    $

    0.93





    $

    (0.55)





    $

    1.48





    7.6

    %



    12.1

    %





    (1)

    Includes amortization and other adjustments related to the purchase accounting for acquisitions.

    (2)

    Represents costs associated with integration and restructuring activities.

    (3)

    Represents transaction costs and financing impacts associated with the acquisition of Edwards Lifesciences' Critical Care Product Group. The transaction costs are recorded in Integration, restructuring and transaction expense and the financing impacts are recorded in Interest income and Interest expense.

    (4)

    Represents costs recorded to Other operating expense (income), net incurred in connection with the separation of BD's former Diabetes Care business.

    (5)

    Represents costs incurred to develop processes and systems to establish initial compliance with the European Union Medical Device Regulation and the European Union In Vitro Diagnostic Medical Device Regulation, which represent a significant, unusual change to the existing regulatory framework. We consider these costs to be duplicative of previously incurred costs and/or one-off costs, which are limited to a specific period of time. These expenses, which are recorded in Cost of products sold and Research and development expense, include the cost of labor, other services and consulting (in particular, research and development and clinical trials) and supplies, travel and other miscellaneous costs.

    (6)

    Includes certain (income) expense items which are not part of ordinary operations and affect the comparability of the periods presented. Such items may include certain product remediation costs, certain legal matters, certain investment gains and losses, certain asset impairment charges, and certain pension settlement costs. The amount in 2024 reflects the recognition of $67 million in accruals as an impact to Revenues resulting from recent developments relating to the Italian government medical device pay back legislation, as well as another legal matter, and which substantially relate to years prior to our current fiscal year. The amount in 2024 also reflects charges to Other operating expense (income), net related to legal matters, including a $175 million charge to accrue an estimated liability for the SEC investigation with respect to, among other things, certain reporting issues involving BD Alaris™ infusion pumps included in SEC disclosures prior to 2021, based on discussions with the SEC with respect to a potential resolution of this matter. The Company cannot anticipate the timing, scope, outcome or ultimate impact of the SEC investigation, financial or otherwise, including but not limited to what actions the SEC might pursue against the Company and/or individuals. As a result, the ultimate resolution is unknown at this time, and it is possible that the amount of the Company's liability could significantly exceed its currently accrued amount. The amount in 2023 includes a charge of $653 million to adjust the estimate of future product remediation costs to Cost of products sold and a charge of $57 million related to pension settlement costs to Other expense, net. The amount in 2023 also includes a gain of $268 million related to the sale of our Surgical Instrumentation platform recorded to Other operating expense (income), net.

     

    BECTON DICKINSON AND COMPANY

    SUPPLEMENTAL INFORMATION

    FY 2025 OUTLOOK RECONCILIATION

     





    Full Year FY 2024



    Full Year FY 2025 Outlook





    ($ in millions)



    % Change



    Revenues

    BDX Reported Revenues



    $

    20,178











    Add: Revenue Adjustment Impact



    67











    Adjusted Revenues



    $

    20,245

























    FY 2025 Reported Revenue Growth







    +8.9% to +9.4%





    Revenue Adjustment Impact







    ~+35 basis points





    Illustrative Foreign Currency (FX) Impact







    (~25) basis points





    FY 2025 Revenue Growth (adjusted)(FXN)







    +8.8% to 9.3%





    FY 2025 Inorganic Impact to Revenue Growth







    ~+475 basis points





    FY 2025 Organic Revenue Growth(FXN)







    +4.0% to +4.5%



















    Total FY 2025 Revenues











    ~$21.9 to $22.1 billion



    Notes

    - Revenue Adjustment Impact reflects the recognition of accruals resulting from recent developments relating to the Italian government medical device pay back legislation, as well as another legal matter, and which substantially relate to years prior to the current fiscal year.

    - Inorganic revenue adjustment is defined as the amount of incremental revenue attributable to acquisitions and the revenue decline attributable to divestitures during the first 12 months post-acquisition/divestiture.

     

    BECTON DICKINSON AND COMPANY

    SUPPLEMENTAL INFORMATION

    FY 2025 OUTLOOK RECONCILIATION CONTINUED

     









    Full Year FY 2025 Outlook





    Full Year FY 2024 from Continuing Operations



    Total Company

    Reported Diluted Earnings per Share



    $

    5.93











    Purchase accounting adjustments ($1.503 billion pre-tax) (1)



    5.16











    Integration costs ($23 million pre-tax) (2)



    0.08











    Restructuring costs ($387 million pre-tax) (2)



    1.33











    Transaction Costs ($48 million pre-tax) (3)



    0.17











    Financing Costs (($8) million pre-tax) (3)



    (0.03)











    Separation-related items ($13 million pre-tax) (4)



    0.05











    European regulatory initiative-related costs ($104 million pre-tax) (5)



    0.36











    Product, litigation, and other items ($318 million pre-tax) (6)



    1.09











    Tax impact of specified items and other tax related (($290) million)



    (1.00)











    Adjusted Diluted Earnings per Share



    $

    13.14





    $14.25 to $14.60

    Reported % Change







    +8.5% to +11.0%





    (1)

    Includes amortization and other adjustments related to the purchase accounting for acquisitions.

    (2)

    Represents costs associated with integration and restructuring activities.

    (3)

    Represents transaction costs and financing impacts associated with the acquisition of Edwards Lifesciences' Critical Care Product Group. The transaction costs are recorded in Integration, restructuring and transaction expense and the financing impacts are recorded in Interest income and Interest expense.

    (4)

    Represents costs recorded to Other operating expense (income), net incurred in connection with the separation of BD's former Diabetes Care business.

    (5)

    Represents costs incurred to develop processes and systems to establish initial compliance with the European Union Medical Device Regulation and the European Union In Vitro Diagnostic Medical Device Regulation, which represent a significant, unusual change to the existing regulatory framework. We consider these costs to be duplicative of previously incurred costs and/or one-off costs, which are limited to a specific period of time. These expenses, which are recorded in Cost of products sold and Research and development expense, include the cost of labor, other services and consulting (in particular, research and development and clinical trials) and supplies, travel and other miscellaneous costs.

    (6)

    Includes certain (income) expense items which are not part of ordinary operations and affect the comparability of the periods presented. Such items may include certain product remediation costs, certain legal matters, certain investment gains and losses, certain asset impairment charges, and certain pension settlement costs. The amount in 2024 reflects the recognition of $67 million in accruals as an impact to Revenues resulting from recent developments relating to the Italian government medical device pay back legislation, as well as another legal matter, and which substantially relate to years prior to our current fiscal year. The amount in 2024 also reflects charges to Other operating expense (income), net related to legal matters, including a $175 million charge to accrue an estimated liability for the SEC investigation with respect to, among other things, certain reporting issues involving BD Alaris™ infusion pumps included in SEC disclosures prior to 2021, based on discussions with the SEC with respect to a potential resolution of this matter. The Company cannot anticipate the timing, scope, outcome or ultimate impact of the SEC investigation, financial or otherwise, including but not limited to what actions the SEC might pursue against the Company and/or individuals. As a result, the ultimate resolution is unknown at this time, and it is possible that the amount of the Company's liability could significantly exceed its currently accrued amount.

     

    Cision View original content:https://www.prnewswire.com/news-releases/bd-reports-fourth-quarter-and-full-year-fiscal-2024-financial-results-302298182.html

    SOURCE BD (Becton, Dickinson and Company)

    Get the next $BDX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BDX

    DatePrice TargetRatingAnalyst
    5/22/2025$185.00Buy → Neutral
    Citigroup
    5/2/2025$185.00Overweight → Neutral
    Piper Sandler
    5/2/2025$192.00Buy → Neutral
    Goldman
    5/2/2025Outperform → Mkt Perform
    Raymond James
    5/1/2025Overweight → Equal Weight
    Wells Fargo
    5/1/2025$190.00Buy → Neutral
    BofA Securities
    5/1/2025Outperform → Mkt Perform
    William Blair
    10/1/2024$255.00 → $275.00Neutral → Buy
    Citigroup
    More analyst ratings

    $BDX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BD to Initiate Real-World Patient Data Registry for the Rotarex™ Atherectomy System in Treatment of Peripheral Artery Disease

      FRANKLIN LAKES, N.J., May 28, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced plans to initiate a patient data registry for the Rotarex™ Atherectomy System to measure real-world outcomes for patients with peripheral artery disease (PAD). Known as "XTRACT," this prospective, multi-center, single-arm, post-market registry study will assess the clinical performance of the Rotarex™ Atherectomy System in the treatment of U.S. patients with PAD lesions. The XTRACT Registry is being led in partnership wi

      5/28/25 6:50:00 AM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • BD to Present at Goldman Sachs 46th Annual Global Healthcare Conference

      FRANKLIN LAKES, N.J., May 27, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that it will present at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 2:00 pm Eastern Time. The live webcast of BD's presentation can be accessed from the BD investor relations website, investors.bd.com. A replay of the event will be available on the same webpage following its conclusion. About BDBD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports

      5/27/25 4:15:00 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • Cancer Patients Face Elevated Risk of Carrying Antimicrobial Resistant 'Superbugs'

      FRANKLIN LAKES, N.J., May 21, 2025 /PRNewswire/ -- First-of-their-kind studies published in The Lancet Oncology1 and Cancer Medicine2 provide new data showing that cancer patients in both hospital and outpatient settings are at a substantially higher risk of developing antimicrobial resistant (AMR) infections compared to all other non-cancer patients. Key Takeaways: The studies, led by the Cancer and AMR Consortium, which includes BD (Becton, Dickinson and Company) (NYSE:BDX), the Union for International Cancer Control (UICC), and the AMR Action Fund, found AMR rates among ke

      5/21/25 6:38:00 AM ET
      $BDX
      Medical/Dental Instruments
      Health Care

    $BDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Becton Dickinson downgraded by Citigroup with a new price target

      Citigroup downgraded Becton Dickinson from Buy to Neutral and set a new price target of $185.00

      5/22/25 8:18:13 AM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • Becton Dickinson downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Becton Dickinson from Overweight to Neutral and set a new price target of $185.00

      5/2/25 8:06:47 AM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • Becton Dickinson downgraded by Goldman with a new price target

      Goldman downgraded Becton Dickinson from Buy to Neutral and set a new price target of $192.00

      5/2/25 8:06:36 AM ET
      $BDX
      Medical/Dental Instruments
      Health Care

    $BDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Henderson Jeffrey William bought $350,430 worth of shares (1,500 units at $233.62), increasing direct ownership by 23% to 8,015 units (SEC Form 4)

      4 - BECTON DICKINSON & CO (0000010795) (Issuer)

      2/10/25 5:03:18 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care

    $BDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP and Chief ISC Officer Shan David sold $199,608 worth of shares (1,166 units at $171.19), decreasing direct ownership by 20% to 4,575 units (SEC Form 4)

      4 - BECTON DICKINSON & CO (0000010795) (Issuer)

      6/2/25 6:44:56 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Jones Christopher Ian Montague

      4 - BECTON DICKINSON & CO (0000010795) (Issuer)

      5/7/25 7:22:33 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Byington Carrie L

      4 - BECTON DICKINSON & CO (0000010795) (Issuer)

      5/7/25 7:20:56 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care

    $BDX
    SEC Filings

    See more
    • SEC Form 11-K filed by Becton Dickinson and Company

      11-K - BECTON DICKINSON & CO (0000010795) (Filer)

      6/27/25 4:59:22 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • SEC Form 11-K filed by Becton Dickinson and Company

      11-K - BECTON DICKINSON & CO (0000010795) (Filer)

      6/27/25 4:58:08 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • Becton Dickinson and Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - BECTON DICKINSON & CO (0000010795) (Filer)

      6/16/25 4:32:00 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care

    $BDX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • November 23, 2021 - Coronavirus (COVID-19) Update: November 23, 2021

      For Immediate Release: November 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On Nov. 22, the FDA authorized three over-the-counter (OTC) COVID-19 antigen diagnostic tests for people age 14 years or older with a self-collected nasal swab sample or people age 2 years or older when an adult collects the nasal swa

      11/23/21 3:16:12 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • July 23, 2021 - Coronavirus (COVID-19) Update: July 23, 2021

      For Immediate Release: July 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: The agency updated its FDA COVID-19 Response At-A-Glance Summary, which provides a quick look at facts, figures and highlights on the FDA's response efforts. On Thursday, July 22 the FDA issued an Emergency Use Authorization (EUA) to Bec

      7/23/21 4:06:11 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care

    $BDX
    Leadership Updates

    Live Leadership Updates

    See more
    • BD Names Gregory J. Hayes to Board of Directors

      FRANKLIN LAKES, N.J., March 27, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the appointment of Gregory J. Hayes to its board of directors, effective March 26, 2025. Hayes, 64, is currently the executive chairman of the board of directors of RTX Corporation, the world's largest aerospace and defense company. He brings more than 30 years of extensive executive experience, having held chief executive officer and senior leadership roles across finance, corporate strategy and business development f

      3/27/25 4:15:00 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of Directors

      SAN DIEGO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. ("Maravai" or the "Company") (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that Carl Hull will retire from his position as Executive Chairman of the Board and that the Board of Directors has unanimously elected R. Andrew Eckert to succeed him as Chairman of the Board, effective December 5, 2024. Carl Hull founded Maravai in 2014 and served as Chief Executive Officer, assuming the role of Executive Chairman in October 2022. "Leading Maravai has been the single most rewarding experience in my career. I am extremely proud of what we have

      12/5/24 4:05:00 PM ET
      $BDX
      $FTRE
      $MRVI
      Medical/Dental Instruments
      Health Care
      Medical Specialities
      Biotechnology: Pharmaceutical Preparations
    • Revelyst Announces Chief Supply Chain Officer

      Revelyst is thrilled to appoint longtime supply chain and business operations leader Joe Beck to the position of Chief Supply Chain Officer. Revelyst, a collective of world-class maker brands that design and manufacture performance gear and precision technologies and a segment of Vista Outdoor Inc. (NYSE:VSTO), today announced the appointment of Joe Beck as Chief Supply Chain Officer, effective April 22. In the third quarter, Revelyst launched GEAR Up, the company's plan to simplify its business model, deliver increased efficiency and profitability, and reinvest in its highest potential brands to accelerate growth and transformation. The appointment of a seasoned, transformational supply

      4/23/24 7:00:00 AM ET
      $BDX
      $EMBC
      $VSTO
      Medical/Dental Instruments
      Health Care
      Ordnance And Accessories
      Industrials

    $BDX
    Financials

    Live finance-specific insights

    See more
    • BD Reports Second Quarter Fiscal 2025 Financial Results

      Revenue of $5.3 billion increased 4.5% as reported, 6.0% currency-neutral and 0.9% organicGAAP and adjusted diluted EPS of $1.07 and $3.35, respectivelyCompany updates full-year fiscal 2025 guidance and provides estimated tariff impactFRANKLIN LAKES, N.J., May 1, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced results for its fiscal 2025 second quarter, which ended March 31, 2025. "Amid a difficult operating environment impacting near-term organic revenue growth, our Q2 results reflect the strength of our business model and ability to exceed our earnings expectations through quality gross margin improvement," s

      5/1/25 6:30:00 AM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • BD Board Declares Dividend

      FRANKLIN LAKES, N.J., April 29, 2025 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $1.04 per common share, payable on June 30, 2025 to holders of record on June 9, 2025. The indicated annual dividend rate is $4.16 per share. About BDBD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advanc

      4/29/25 4:20:00 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • BD Reports First Quarter Fiscal 2025 Financial Results

      Company Delivers Revenue, Margin and Earnings Ahead of its Expectations Revenue of $5.2 billion increased 9.8% as reported, 9.6% currency-neutral and 3.9% organicGAAP and adjusted diluted EPS of $1.04 and $3.43 grew 8.3% and 28.0%, respectivelyBD completes $750 million share repurchase to date in FY25Company increases FY25 adjusted diluted EPS guidance at the midpoint while absorbing translational currency1FRANKLIN LAKES, N.J., Feb. 5, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced results for its fiscal 2025 first quarter which ended December 31, 2024. "We delivered strong operational performance in Q1, with

      2/5/25 4:30:00 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care

    $BDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Becton Dickinson and Company (Amendment)

      SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)

      2/16/24 4:29:42 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Becton Dickinson and Company (Amendment)

      SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)

      2/14/24 10:02:59 AM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Becton Dickinson and Company (Amendment)

      SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)

      2/13/24 5:00:53 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care